[go: up one dir, main page]

DK3265085T3 - Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser - Google Patents

Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser Download PDF

Info

Publication number
DK3265085T3
DK3265085T3 DK16711733.2T DK16711733T DK3265085T3 DK 3265085 T3 DK3265085 T3 DK 3265085T3 DK 16711733 T DK16711733 T DK 16711733T DK 3265085 T3 DK3265085 T3 DK 3265085T3
Authority
DK
Denmark
Prior art keywords
treatment
methods
movement disorders
involuntary movement
abnormal involuntary
Prior art date
Application number
DK16711733.2T
Other languages
English (en)
Inventor
David Stamler
Michael Fangching Huang
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55590145&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3265085(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3265085T3 publication Critical patent/DK3265085T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Prostheses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16711733.2T 2015-03-06 2016-03-07 Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser DK3265085T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562129616P 2015-03-06 2015-03-06
US201562175112P 2015-06-12 2015-06-12
US201562180012P 2015-06-15 2015-06-15
PCT/US2016/021238 WO2016144901A1 (en) 2015-03-06 2016-03-07 Methods for the treatment of abnormal involuntary movement disorders

Publications (1)

Publication Number Publication Date
DK3265085T3 true DK3265085T3 (da) 2022-10-03

Family

ID=55590145

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16711733.2T DK3265085T3 (da) 2015-03-06 2016-03-07 Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser

Country Status (24)

Country Link
US (9) US20160287574A1 (da)
EP (2) EP4140483A1 (da)
JP (3) JP6932641B2 (da)
KR (3) KR20230003264A (da)
CN (4) CN114767672A (da)
AU (2) AU2016229949B2 (da)
CA (2) CA3236214A1 (da)
CL (1) CL2017002223A1 (da)
DK (1) DK3265085T3 (da)
EA (1) EA201791977A1 (da)
ES (1) ES2927262T3 (da)
HK (1) HK1249860A1 (da)
HR (1) HRP20221106T1 (da)
HU (1) HUE059747T2 (da)
IL (3) IL305352A (da)
LT (1) LT3265085T (da)
MX (2) MX385368B (da)
PL (1) PL3265085T3 (da)
PT (1) PT3265085T (da)
RS (1) RS63647B1 (da)
SG (1) SG11201706959TA (da)
UA (1) UA129759C2 (da)
WO (1) WO2016144901A1 (da)
ZA (2) ZA201706131B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2883641C (en) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN114767672A (zh) 2015-03-06 2022-07-22 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
MY193767A (en) 2015-10-30 2022-10-27 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
US10160757B2 (en) 2015-12-23 2018-12-25 Neuroscrine Biosciences, Inc. Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
WO2017221169A1 (en) * 2016-06-24 2017-12-28 Lupin Limited Premixes of deutetrabenazine
MX394415B (es) 2017-01-27 2025-03-24 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2).
WO2018170214A1 (en) 2017-03-15 2018-09-20 Zhang Chengzi Analogs of deutetrabenazine, their preparation and use
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CN111343985A (zh) 2017-11-08 2020-06-26 逸达生物科技股份有限公司 二氢丁苯那嗪的酯
IL278185B2 (en) 2018-04-25 2024-11-01 Shinkei Therapeutics Inc Tetrabenazine transdermal delivery device
US20190374521A1 (en) * 2018-06-10 2019-12-12 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion
US20200345663A1 (en) * 2018-06-10 2020-11-05 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion
CR20200616A (es) * 2018-06-10 2021-03-15 Axsome Therapeutics Inc Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión
KR20210044817A (ko) 2018-08-15 2021-04-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US12152087B2 (en) 2018-10-18 2024-11-26 Oncopeptides Innovation Ab Deuterated melflufen compounds
CA3123393A1 (en) 2018-12-13 2020-06-18 Auspex Pharmaceuticals, Inc. Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
CN109793745B (zh) * 2019-01-24 2021-05-25 遵义医科大学 阿司匹林在制备治疗异动症药物中的应用及其药物组合物
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EP4048268A4 (en) * 2019-10-22 2023-11-29 Shinkei Therapeutics, Inc. TETRABENAZINE TRANSDERMAL DELIVERY DEVICE
WO2021252741A1 (en) * 2020-06-10 2021-12-16 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US20220296585A1 (en) * 2020-06-10 2022-09-22 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US20240197714A1 (en) * 2021-04-15 2024-06-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
BR112023021257A2 (pt) * 2021-04-15 2023-12-12 Neurocrine Biosciences Inc Métodos para a administração combinada de deutetrabenzina e um cyp2d6
IL322593A (en) 2023-02-10 2025-10-01 Teva Pharma Detection and assessment of movement disorder
WO2025188830A1 (en) * 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) 1958-07-15 Method for preparing same
US2830993A (en) 1958-04-15 Quinolizine derivatives
US3045021A (en) 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
HU175890B (en) 1977-06-15 1980-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new 1,2,3,4,6,7-hexahydro-11-b-alpha-benzo-square bracket-a-square brecket closed-quinolyzine derivatives
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4316897A (en) 1980-09-10 1982-02-23 Hoffmann-La Roche Inc. Method of lowering serum prolactin
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
KR19990035817A (ko) 1995-07-24 1999-05-25 피터 지. 스트링거 주의력 결핍증/활동항진증의 치료 방법
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
GB9817028D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US7260823B2 (en) 2001-01-11 2007-08-21 Prime Research Alliance E., Inc. Profiling and identification of television viewers
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ATE234299T1 (de) 1999-12-03 2003-03-15 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
EP1134290A3 (en) 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20020183553A1 (en) 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US7030164B2 (en) 2001-12-05 2006-04-18 Wyeth Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
AU2004249211A1 (en) 2003-06-16 2004-12-29 Andrx Pharmaceuticals, Llc Oral extended-release composition
US20050153953A1 (en) 2003-11-21 2005-07-14 Crista Trippodi-Murphy Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
US7367953B2 (en) 2003-11-26 2008-05-06 Ge Medical Systems Global Technology Company Method and system for determining a period of interest using multiple inputs
US20100018408A1 (en) 2004-02-06 2010-01-28 Lassota Zbigniew G Brew basket assembly and brewer
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
EP1750717B1 (en) 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
JP5199678B2 (ja) 2005-02-23 2013-05-15 プレクサ ファーマシューティカルズ， インコーポレイテッド 運動障害および他のｃｎｓ適応症の処置に使用することにおけるドーパミントランスポータ阻害剤
US20080299204A1 (en) 2005-06-23 2008-12-04 Spherics, Inc. Dosage forms for movement disorder treatment
US20080033011A1 (en) 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
ES2587368T3 (es) 2006-02-17 2016-10-24 Ratiopharm Gmbh Derivados deuterados de catecolamina y medicamentos que comprenden dichos compuestos
BRPI0711481A8 (pt) 2006-05-02 2017-11-28 Univ Michigan Regents derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens
HU227610B1 (en) 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
MX2009003743A (es) 2006-10-12 2009-06-18 Novartis Ag Uso de ciclosporinas modificadas.
PT2081929E (pt) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados
CA2673137C (en) 2006-11-21 2015-02-10 Rigel Pharmaceuticals, Inc. Prodrug salts of 2,4-pyrimidinediamine compounds and their uses
US20100204258A1 (en) 2007-03-12 2010-08-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
LT2125698T (lt) 2007-03-15 2016-10-10 Auspex Pharmaceuticals, Inc. Deuterintas d9-venlafaksinas
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US9827210B2 (en) 2007-06-29 2017-11-28 Phovitreal Pty Ltd Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
US7902364B2 (en) 2007-11-29 2011-03-08 General Electric Company Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
WO2009124357A1 (en) 2008-04-10 2009-10-15 Malvin Leonard Eutick Fast dissolving oral formulations for critical drugs
US9012471B2 (en) 2008-04-11 2015-04-21 The Trustees Of Columbia University In The City Of New York Glucose metabolism modulating compounds
JP5207852B2 (ja) 2008-06-30 2013-06-12 三洋電機株式会社 太陽電池及びその製造方法
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US20100018969A1 (en) 2008-07-24 2010-01-28 Feature Foods, Inc. Packaging for food products
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
NO3061760T3 (da) 2008-09-18 2018-04-07
US20100113496A1 (en) 2008-09-25 2010-05-06 Auspex Pharmaceuticals, Inc. Piperidine modulators of vmat2
US20120053159A1 (en) 2009-02-11 2012-03-01 Muller George W Isotopologues of lenalidomide
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
US8658236B2 (en) 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
BR112012020585A2 (pt) 2010-02-24 2018-04-17 Auspex Pharmaceuticals Inc composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011153157A2 (en) 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
US9321095B2 (en) 2010-06-30 2016-04-26 General Electric Company Apparatuses and methods for cutting porous substrates
US9676810B2 (en) 2010-07-08 2017-06-13 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
WO2012028635A1 (en) * 2010-09-03 2012-03-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Deuterated analogs of pridopidine useful as dopaminergic stabilizers
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2012081031A1 (en) 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
HUE026715T2 (en) 2011-01-20 2016-07-28 Bionevia Pharmaceuticals Inc Modified release pharmaceutical composition comprising Epalrestat or a derivative thereof and methods of their use
WO2012100202A1 (en) 2011-01-22 2012-07-26 Filippo Costanzo Dynamic 2d and 3d gestural interfaces for audio video players capable of uninterrupted continuity of fruition of audio video feeds
PE20141839A1 (es) 2011-06-24 2014-11-20 Directv Group Inc Metodo y sistema para obtener datos de visualizacion y proporcionar recomendaciones de contenido a un decodificador de senales digitales
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
KR101362482B1 (ko) 2012-01-31 2014-02-12 한국과학기술연구원 테트라베나진과 다이하이드로테트라베나진의 제조방법
WO2013142816A1 (en) 2012-03-23 2013-09-26 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders
CA2883641C (en) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN102936246A (zh) 2012-11-08 2013-02-20 江苏暨明医药科技有限公司 丁苯那嗪的合成方法
HK1219095A1 (zh) 2013-01-31 2017-03-24 Auspex Pharmaceuticals, Inc. Vmat2的benzoquinolone抑制剂
US20160207917A1 (en) 2013-09-27 2016-07-21 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2015077521A1 (en) 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
HK1224294A1 (zh) 2013-11-22 2017-08-18 Auspex Pharmaceuticals, Inc. 治疗异常肌肉活动的方法
BR112016012747B1 (pt) 2013-12-03 2022-07-12 Auspex Pharmaceuticals, Inc Processo de preparação de uma mistura racêmica de (rr,ss)-d6-tetrabenazina
MX2016009817A (es) 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
US10166183B2 (en) 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
CN114767672A (zh) 2015-03-06 2022-07-22 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
CN117915901A (zh) * 2021-04-15 2024-04-19 纽罗克里生物科学有限公司 氘代丁苯那嗪和cyp2d6抑制剂的联合施用方法

Also Published As

Publication number Publication date
JP2022109989A (ja) 2022-07-28
PT3265085T (pt) 2022-09-05
US20170151227A1 (en) 2017-06-01
US20210275517A1 (en) 2021-09-09
IL288712B2 (en) 2024-01-01
PL3265085T3 (pl) 2022-11-07
CA2978006A1 (en) 2016-09-15
JP7066902B2 (ja) 2022-05-13
KR20230003264A (ko) 2023-01-05
HK1249860A1 (zh) 2018-11-16
US20210379051A1 (en) 2021-12-09
HK1248609A1 (en) 2018-10-19
US20160287574A1 (en) 2016-10-06
EP3265085B1 (en) 2022-07-20
KR102528845B1 (ko) 2023-05-08
IL288712A (en) 2022-02-01
CA3236214A1 (en) 2016-09-15
MX2021009830A (es) 2021-09-08
US20240316035A1 (en) 2024-09-26
US11648244B2 (en) 2023-05-16
SG11201706959TA (en) 2017-09-28
EP4140483A1 (en) 2023-03-01
KR20240049625A (ko) 2024-04-16
HUE059747T2 (hu) 2022-12-28
CN114767672A (zh) 2022-07-22
ES2927262T3 (es) 2022-11-03
HRP20221106T1 (hr) 2022-11-25
NZ735000A (en) 2024-02-23
ZA201902108B (en) 2021-09-29
CN114788824A (zh) 2022-07-26
KR102335744B1 (ko) 2021-12-07
MX385368B (es) 2025-03-18
IL254121A0 (en) 2017-10-31
AU2016229949B2 (en) 2021-04-08
CL2017002223A1 (es) 2018-06-08
LT3265085T (lt) 2022-11-10
AU2021204740A1 (en) 2021-08-05
RS63647B1 (sr) 2022-11-30
JP6932641B2 (ja) 2021-09-08
JP2018507248A (ja) 2018-03-15
CA2978006C (en) 2024-06-25
US20180064701A1 (en) 2018-03-08
US10959996B2 (en) 2021-03-30
US11357772B2 (en) 2022-06-14
ZA201706131B (en) 2019-09-25
US20210145820A1 (en) 2021-05-20
CN107624067A (zh) 2018-01-23
AU2016229949A1 (en) 2017-09-21
IL254121B (en) 2022-01-01
US11446291B2 (en) 2022-09-20
EA201791977A1 (ru) 2018-01-31
UA129759C2 (uk) 2025-07-30
KR20170122820A (ko) 2017-11-06
MX2017011459A (es) 2018-04-24
KR20210149246A (ko) 2021-12-08
WO2016144901A1 (en) 2016-09-15
US20180318281A1 (en) 2018-11-08
IL305352A (en) 2023-10-01
IL288712B1 (en) 2023-09-01
US11564917B2 (en) 2023-01-31
EP3265085A1 (en) 2018-01-10
JP2021183630A (ja) 2021-12-02
US20170326131A1 (en) 2017-11-16
US12016858B2 (en) 2024-06-25
CN114796209A (zh) 2022-07-29
AU2021204740B2 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
DK3265085T3 (da) Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser
IL285151A (en) Methods of treating fgf21-associated disorders
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3261640T3 (da) 5ht-agonister til behandling af epilepsilidelser
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3285803T3 (da) Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3288577T3 (da) Adiponectin-peptidomimetika til behandling af øjenlidelser
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
IL255185A0 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3307267T3 (da) Behandling af multipel sklerose
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3209295T4 (da) Fremgangsmåder til behandling af øjenlidelser
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner
DK3049100T3 (da) Modificerede fibroblastvækstfaktorer-1 til behandling af øjenlidelser
DK3448382T3 (da) Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
DK3458067T3 (da) Behandling af neurologiske lidelser